Novo Nordisk is pausing advertisements for its weight problems drug Wegovy because it struggles to maintain up with surging demand, the most recent hurdle in its rollout of the burden loss drug.
“To keep away from stimulating additional demand for this medication, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker stated in an emailed assertion. “We’re pausing all native tv promoting and suspending deliberate nationwide tv promoting for Wegovy. We’re additionally assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The information was earlier reported by Endpoints.
Wegovy, which incorporates the lively ingredient semaglutide, has turn into immensely in style for its effectiveness in serving to folks drop pounds and helps usher in what many see as a sea change in weight problems therapy. Its sister drug for diabetes, Ozempic, has additionally been in demand for the same impact on weight reduction.
Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!
GET STARTED